Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED
大健康國際集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2211)

FORECASTED INTERIM RESULTS – SIGNIFICANT INCREASE IN LOSS

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the shareholders and potential investors of the Company that, based on the preliminary review of the unaudited consolidated management accounts of the Group and the current available information to the Board, the interim results of the Group is expected to record a loss of not less than RMB255 million (equivalent to approximately HK$303 million*) for the six months ended 31 December 2020, representing an increase of approximately 49% as compared to the loss in the corresponding period of last year.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

This announcement is made by Universal Health International Group Holding Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**").

The board of directors (the "**Directors**") of the Company (the "**Board**") wishes to inform the shareholders and potential investors of the Company that, based on the preliminary review of the unaudited consolidated management accounts of the Group and the current available information to the Board, the interim results of the Group is expected to record a loss of not less than RMB255 million (equivalent to approximately HK$303 million*) for the six months ended 31 December 2020 (the "**Period**"), representing an increase of approximately 49% as compared to the loss in the corresponding period of last year. Details of which will be disclosed in the results announcement to be published in late February 2021.

The Board considers that the expected increase in loss recorded for the Period as compared to the corresponding period of last year was mainly attributable to the following factors:

(i) the outbreak of the epidemic arouse the awareness of prevention of diseases of the nationals, which strengthens their immune system and reduces sickness;

(ii) the vigorous development and competition of various e-commerce platforms have affected the sales of physical stores;

(iii) increase in the number of competitors; and

(iv) the purchasing power of the population has declined due to the economic downturn.

Despite the expected increase in loss for the Period as compared to the loss recorded for the corresponding period of last year, the Board strives to strengthen its internet sales and marketing and promotion efforts to mitigate the adverse effects of the external environment.

The information contained in this announcement is prepared based on the Board's preliminary review of the unaudited consolidated management accounts of the Group and the current available information to the Board, but not on any data or information which has been audited or reviewed by the auditors of the Company. The Company is still finalizing the results of the Group for the Period and will disclose it in the results announcement to be published in late February 2021.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Universal Health International Group Holding Limited
Jin Dongtao
Chairman

Hong Kong, 8 February 2021

As at the date of this announcement, the Board comprises four executive directors, namely, Mr. Jin Dongtao, Mr. Jin Dongkun, Mr. Zhao Zehua and Mr. Sun Libo and three independent non-executive directors, namely, Mr. Cheng Sheung Hing, Ms. Chiang Su Hui Susie and Mr. Zou Haiyan.

* *For illustrative purpose of this announcement, conversion of RMB into HK$ is based on the exchange rate of RMB1.00 = HK$1.18816.*